A “sober” assessment of e.l.f.’s strategy and governance is “clearly warranted and long overdue,” says Marathon Partners founder and Managing Partner Mario Cibelli in a letter to the company’s board. E.l.f.’s share price has been on a steady decline as sales growth has slowed, with a roughly flat performance reported by the firm in November for the first three quarters of fiscal 2018.
Marathon Partners Equity Management, LLC, which owns approximately 8.6% of e.l.f. Beauty, Inc.’s common stock, continues to push for aggressive changes at the company, including in the areas of operating strategy, governance and executive compensation, to shrink costs and return value to shareholders.
E.l.f.’s share price has been on a sinking trajectory over the last couple of years since its smash initial public...
Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
